GI Effects® Comprehensive Profile - Stool

The Most Comprehensive Stool Test for Optimal Clinical Utility

The GI Effects® Comprehensive Stool Profile is an advanced stool test that provides immediate, actionable clinical information for the management of gastrointestinal health. Utilizing cutting-edge technologies and biomarkers, this test offers valuable insight into digestive function, intestinal inflammation, and the intestinal microbiome.

GI Effects 2200 is not available in NY

Genova Diagnostics is excited to announce the addition of polymerase chain reaction (PCR) for parasites to the GI Effects Profiles. PCR is a highly sensitive and specific methodology that detects an organism's DNA.

The GI Effects now includes 6 PCR targets that detect common protozoan parasites:

  • Blastocystis spp. with reflex subtyping 1-9
  • Cryptosporidium spp.
  • Cyclospora cayetanensis
  • Dientamoeba fragilis
  • Entamoeba histolytica
  • Giardia

The 6 PCR targets replace the 3 EIA biomarkers. The GI Effects upgrade also includes several report enhancements for ease of use.

Proceed to Clinical Overview

The Genova Difference

Why Choose Genova Diagnostics' Gastrointestinal Products?

  • GI Effects is a comprehensive assessment of complete GI health, assessing the root cause of most gut complaints.
  • Genova uses a combination of PCR, culture, and microscopic methods to ensure any and all relevant organisms are identified.
  • Genova recovers live organisms (yeast and bacteria) for susceptibility testing and improved treatment options.
  • Genova measures metabolomics and can assess the interaction between the microbiome and its host.
  • Genova is the market authority on stool inflammatory markers, testing calprotectin, EPX and sIgA.
  • Genova has amassed a database of hundreds of thousands of complete stool profiles. Our data driven and evidence-based analysis ensures the highest standard of analytical validity and clinical utility.

Learn more about Genova's Comprehensive GI Testing Value.

Clinical Overview

When Should the GI Effects Comprehensive Stool Profile Be Considered?

The GI Effects Comprehensive Stool Profile can reveal important information about the root cause of many common gastrointestinal symptoms such as gas, bloating, indigestion, abdominal pain, diarrhea, and constipation. This stool analysis utilizes biomarkers such as Calprotectin to differentiate between Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).3,4 In addition, Genova's GI Effects test can be used to evaluate patients with a clinical history that suggests a gastrointestinal infection or dysbiosis.

Gut microbes are codependent with one another and with their human host, and the health of one affects the other. A sizeable volume of research associates a dysbiotic, or imbalanced gut microbiome with multiple disease states both within and outside of the GI tract.1,2 The diverse metabolic activities of the microbiome ultimately impact the human host, and the activities of the human host ultimately affect the health of their microbiome.

The GI Effects Comprehensive Stool Profile Biomarkers

The biomarkers from the GI Effects Comprehensive Profile are reported using the DIG framework, providing key clinical information for three main gastrointestinal functional areas:

  • Digestion/Absorption:
    • Pancreatic Elastase-1 is a marker of exocrine pancreatic function.
    • Products of Protein Breakdown are markers of undigested protein reaching the colon.
    • Fecal Fat is a marker of fat breakdown and absorption.
  • Inflammation/Immunology:
    • Calprotectin is a marker of neutrophil-driven inflammation. Produced in abundance at sites of inflammation, this biomarker has been proven clinically useful in differentiating between Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).3,4
    • Eosinophil Protein X is a marker of eosinophil-driven inflammation and allergic response.
    • Fecal Secretory IgA is a marker of gut secretory immunity and barrier function.
  • Gut Microbiome:
    • Metabolic indicators, including short-chain fatty acids and beta-glucuronidase, demonstrate specific and vital metabolic functions performed by the microbiota.
    • Commensal Bacteria demonstrate the composition and relative abundance of gut organisms.
      • More than 95% of commensal gut organisms are anaerobic and are difficult to recover by traditional (aerobic) culture techniques.
      • GI Effects assesses a set of 24 genera/species that map to 7 major phyla.
    • Bacterial and mycology cultures demonstrate the presence of specific beneficial and pathological organisms.
    • Bacterial and mycology sensitivities are provided for pathogenic or potentially pathogenic organisms that have been cultured. The report includes effective prescriptive and natural agents.
    • Parasitology includes comprehensive testing for all parasites on every parasitology exam ordered.
      • GI Effects provides microscopic fecal specimen examination for ova and parasites (O&P), the gold standard of diagnosis for many parasites.
      • 6 Polymerase chain reaction (PCR) targets detect common protozoan parasites including Blastocystis spp. with reflex subtyping 1-9, Cryptosporidium spp., Cyclospora cayetanensis, Dientamoeba fragilis, Entamoeba histolytica, and Giardia. PCR for organisms is emerging as a highly sensitive method for infectious organism detection.
      • Selection of a one-day or three-day sample collection is based on the clinician's clinical index of suspicion for parasitic infection. If there is no/low suspicion, a one-day sample will likely be adequate. For high suspicion, a three-day sample collection is optimal.
  • Additional Biomarkers Available:
    • Campylobacter
    • Clostridium difficile
    • Escherichia coli
    • Fecal Lactoferrin
    • Helicobacter pylori
    • Macro Exam for Worms
    • Zonulin Family Peptide
    • KOH Preparation for Yeast

What Advantage Does the Profile Offer Compared to Other Diagnostics?

A structured fecal biomarker panel offers the advantage of assessing multiple functional areas that may be contributing to symptoms. For example, diarrhea could stem from multiple causes including pancreatic exocrine insufficiency, inflammation, food allergies, or the presence of a pathogenic or potentially pathogenic organism. A positive result on one or more fecal biomarker tests may guide therapy, either by suggesting a treatable alternative diagnosis or by eliminating a diagnosis from further consideration. The latter allows individualized targeted treatment to be redirected to more likely diagnoses.5,6

GI Effects® represents the best technical available to assess the gut microbiome, combining:

  • 16S rRNA gene polymerase chain reaction (PCR) amplification technique for anaerobic commensal bacteria
  • Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) technology for bacterial and fungal species identification via culture
  • Gold standard microscopic ova and parasite (O&P) detection
  • Real-time PCR for the identification of 6 common parasites
  • Next-Generation DNA sequencing for Blastocystis spp. with reflex subtyping 1-9

The test report is organized so that the clinician may move through results in a logical order that enhances clinical utility, starting with innovative Interpretation-At-A-Glance pages to synthesize the information.

What Can Clinicians and Patients Expect from GI Effects Comprehensive Profile Stool Testing?

The GI Effects Stool Profile biomarkers provide comprehensive information for the development of strategic interventions. Symptoms often improve as identified functional imbalances and inadequacies become normalized through targeted dietary, lifestyle, and supplementation therapeutics.

The GI Effects Interpretive Guide is a convenient tool to support the therapeutic decision-making process for patients with complex gut-related conditions.


References

  1. Marchesi J, et. al. The gut microbiota and host health: a new clinical frontier. Gut. 2016 Feb;65(2):330-9.
  2. Clemente J, et. al. The impact of the gut microbiota on human health: an integrative review. Cell. 2012 Mar;148(6):1258-70.
  3. Menees SB, et. al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015 Mar;110(3):444-54.
  4. Dabritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol. 2014 Jan;20(2):363-375.
  5. Parsons K, et. al. Novel testing enhances irritable bowel syndrome medical management: the IMMINENT study. Glob Adv Health Med. 2014 May;3(3):25-32.
  6. Goepp J, et. al. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. Glob Adv Health Med. 2014 May;3(3):9-15.

Test Type: Stool Test

Analyte List
Acetate %
Akkermansia muciniphila
Anaerotruncus colihominis
Bacteriology
Bacteroides vulgatus
Bacteroides-Prevotella group
Barnesiella spp.
Beta- glucuronidase
Bifidobacterium longum
Bifidobacterium spp.
Butyrivibrio crossotus
Calprotectin
Cholesterol
Clostridium spp.
Collinsella aerofaciens
Color
Consistency
Coprococcus eutactus
Desulfovibrio piger
Eosinophil Protein X (EPX)
Escherichia coli
Faecalibacterium prausnitzii
Fecal Fat (Total)
Fecal Occult Blood
Fecal sIgA
Firmicutes/Bacteroidetes (F/B Ratio)
Fusobacterium spp.
Lactobacillus spp.
Long Chain Fatty Acids
Methanobrevibacter smithii
Mic Sensitivities, Yeast or Bacteria
Microscopic Exam Results
Mycology (Yeast/Fungi)
Odoribacter spp.
Other Biomarkers
Oxalobacter formigenes
Pancreatic Elastase 1
Parasitology
Phospholipids
Prevotella spp.
Products of Protein Breakdown (Total) (Valerate+Isobutyrate+Isovalerate)
Propionate %.
Pseudoflavonifractor spp.
Roseburia spp.
Ruminococcus spp.
SCFA (Total) (Acetate, n-Butyrate, Propionate)
Triglycerides
Veillonella spp.
n-Butyrate %
n-Butyrate Concentration
Specimen Requirements